Fig 1. Modified Rankin scale 0–2 outcomes in pre-IMS, IMS I, and IMS II compared with historical control of NINDS study rtPA and placebo control groups. Time to IV treatment was significantly earlier in the NINDS rtPA trial (108 minutes) compared with that in the 3 IV/IA treatment groups (126, 139, 140 minutes).